Related Experiment Video
Updated: May 16, 2025
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
6.2K
Molecular testing and targeting for solid tumors with CNS metastases
Kate E Therkelsen1, Toni Cao1, Meaghan Roy-O'Reilly1
1Division of Neuro-oncology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Journal of Neuro-Oncology
|April 3, 2025
Summary
Molecular testing for solid tumors is growing. Understanding these tests helps guide treatment for patients with metastatic brain tumors.
Area of Science:
- Oncology
- Molecular Diagnostics
- Neuro-oncology
Background:
- The field of molecular testing for solid tumors is evolving quickly.
- Accurate molecular profiling is crucial for targeted therapy selection.
Purpose of the Study:
- To review current molecular testing options for solid tumors.
- To highlight the implications of these tests for central nervous system (CNS) metastases.
- To inform clinical decision-making in neuro-oncology.
Main Methods:
- Literature review of recent advancements in molecular diagnostics for solid tumors.
- Analysis of testing methodologies and their clinical utility.
- Discussion of challenges and limitations in testing CNS metastases.
Main Results:
- Molecular testing provides actionable insights for a growing number of solid tumors.
- Specific genomic alterations can be targeted with approved therapies.
- Testing limitations exist, particularly for tissue acquisition and analysis in the CNS.
Conclusions:
- Comprehensive molecular testing is essential for optimizing treatment strategies in patients with solid tumors, including those with CNS metastases.
- Continued research is needed to overcome current testing challenges and expand therapeutic options.
